Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619 - Foulon,I.; Bachir,D.; Galacteros,F.; Maclouf,J. (Arterioscler Thromb, 1993)